Objectives Board of Directors Advisory Board Leadership Sponsors
CIB2012 CIB2011 CIB2010 ICTM 2011
Executive Committee Education Committee International Collaboration Committee Communication Committee Membership Committee
Cellular & Molecular Medicine Applied Immunology Molecular Imaging Regenerative medicine Drug development and discovery Biomaterials & Clinical Application Omics Science
ISTM Newsletter Journals
Certification and Diplomate Program Short Term Training Abroad Long Term Abroad Training Fellowship Observer-ships Abroad
Conferences Travel Grants Travel Grants for Short Term Training Abroad Travel Fellowship for Long Term Abroad Training Observer-ships Abroad Grants Excellent in Translational Medicine Award Research Grants
Advisory Board Home>>About ISTM>>Advisory Board
Prof Jeffrey M. Drazen: Dr Drazen is a Professor in the Department of Environmental Health and Distinguished Parker B. Francis Professor of Medicine, Harvard Medical School, Boston, USA. He serves as an Editor-in-Chief of New England Journal of Medicine.
Prof Joseph Loscalzo: Dr. Joseph Loscalzo is Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine, and Physician-in-Chief at Brigham and Women’s Hospital. He served as an associate editor of the New England Journal of Medicine for nine years, Chair of the Cardiovascular Board of the American Board of Internal Medicine, Chair of the Research Committee of the American Heart Association, Chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in the Cardiovascular Sciences, Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of Health a member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a member of the Council of Councils of the National Institutes of Health. He is currently a member of the Institute of Medicine of the US National Academy of Science, Editor-in-Chief of Circulation, and a senior editor of Harrison’s Principles of Internal Medicine.
Prof Mikael Dolsten: Dr. Dolsten is the President of Worldwide Research and Development, Senior Vice President of Pfizer, advancing Pfizer's leadership in small molecule science and medicines. Dr Dolsten also served as the Senior Vice President in Wyeth Inc. and President of Wyeth Research, Executive Vice President at Boehringer Ingelheim and global executive leadership in AstraZeneca and Pharmacia & Upjohn. He has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund. In addition, he is a Fellow of The New York Academy of Medicine (NYAM) and a Governor of the New York Academy of Sciences. Dr Dolsten has published several patents and approximately 150 articles in international journals.
Prof Cindy Dunbar: Dr. Dunbar is a Senior Investigator and Head of the Molecular Hematopoiesis Section within the Hematology Branch of the National Heart, Lung, and Blood Institute. She serves as Editor-in-Chief of the journal Blood.
Prof. Lawrence M. Popescu: Dr Popescu is a Professor of Cellular and Molecular Medicine and Director General of the National Institute of Pathology,Bucharest, Romania. He is currently the President of the Romanian Academy of Medical Sciences. At the European level, he has been elected the Vice-President for 2010-2011 and President-Elect for 2012-2014 of the Federation of European Academies of Medicine. He discovered telocytes, which, in addition to stem cells, may be involved in regeneration/repair of some vital organs, eventually. He is the Editor-in-chief of the Journal of Cellular and Molecular Medicine.
Prof Garret A Fitzgerald: Dr Fitzgerald is a Professor of Medicine and Pharmacology, McNeil Professor in Translational Medicine and Therapeutics, Associate Dean for Translational Research, Chair of Department of Pharmacology, and Director of the Institute for Translational Medicine and Therapeutics. He serves as the member of editorial boards of Journals, e.g. Circulation, Journal of Clinical Investigation, Journal of Pharmacology and Experimental Therapeutics, Trends in Cardiovascular Medicine.
Prof Kenneth B. Adler: Dr. Adler is a professor of molecular biomedical sciences at North Carolina State University College of Veterinary Medicine. He serves as an editor of the American Journal of Respiratory Molecular and Cellular Biology, and associate editor of Respiratory Research.
Prof Baofeng Yang: Dr Yang is the Academician Member of the Chinese Academy of Engineering, Professor of Pharmacology, and President of Harbin Medical University. He is the Founding Chairman of North-East Center for Translational Medicine. He also serves as the Director of State-Province Key Laboratories of Biomedicine-Pharmaceutics of China and the Member of the Committee of Science and Technology, Ministry of Education, the Evaluation Committee, National Natural Science Foundation of China, and the National New Drug Evaluation Committee, China.
Prof Elazer Edelman: Dr Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at Massachusetts Institute of Technology and a Professor of Medicine at Harvard Medical School. He is a Senior Physician at the Brigham and Women’s Hospital. He also serves as the Director of the Harvard-MIT Biomedical Engineering Center, Health Sciences and Technology, at Massachusetts Institute of Technology and as Senior Scientific Advisor of Science: Translational Medicine.
Prof M. Elizabeth Fini: Dr. Fini is the Vice Dean for Research at the Keck School of Medicine, University of Southern California. She also serves as Director, USC Institute for Genetic Medicine. She is appointed as professor of cell & neurobiology and holds a secondary appointment as professor of ophthalmology at the Doheny Eye Institute. Dr. Fini’s research centers on mechanisms of tissue injury, repair and regeneration, especially with respect to the eye and its diseases. In 2001 she was co-awarded the Rudin Glaucoma Prize from the New York Academy of Medicine for her collaborative work on a novel unifying mechanism for glaucoma pathogenesis. She is the author of over 100 publications in the scientific literature and is an inventor who holds multiple patents. She serves on numerous national and international advisory boards and committees.
Prof. Murray Korc: Dr Korc is the Joseph M. Huber Professor of Medicine, Professor of Pharmacology and Toxicology at Dartmouth Medical School, and Professor of The Dartmouth Institute for Health Policy and Clinical Practice. He joined Dartmouth Hitchcock Medical Center in 2003 as chair of the Department of Medicine, and as a member of the Section of Endocrinology. Dr. Korc is also the scientific director of the Pancreatic Cancer Program within the Norris Cotton NCI-designated Comprehensive Cancer Center. In addition, he was the founding Director of the Program for Experimental and Molecular Medicine, which is a Dartmouth Medical School-based PhD granting training in translational research. From 2008 till 2010 he was also the Associate Dean for Clinical and Translational Research at Dartmouth.
Prof Joseph S. Alpert: Dr Alpert is the Professor of Medicine in the Department of Medicine at the University of Arizona College of Medicine (UA COM) at Tucson and Editor-in-Chief of the American Journal of Medicine. He served as Director of coronary care at the Naval Regional Medical Center in San Diego,Head of the Samuel A. Levine Cardiac Unit at Brigham Hospital and Professor and Director of the Division of Cardiovascular Medicine at the University of Massachusetts Medical School. Dr. Alpert is a Master of the American College of Physicians and a fellow of the American Heart Association, the American College of Cardiology (ACC), the American College of Chest Physicians, and the European Society of Cardiology. He has received many awards for excellence in teaching from the Brigham Hospital, the United States Navy, the University of Massachusetts, and the UA COM. In 2004, he received the Gifted Teacher Award from the ACC. He has served on the Boards of Trustees of the ACC, the American Board of Internal Medicine, and the Association of University Professors. He has authored 48 books and monographs and more than 600 publications.
Prof S. Claiborne Johnston: Dr Johnston is Associate Vice Chancellor of Research, Director of the Clinical and Translational Science Institute, Professor of Neurology and Epidemiology, and Director of the Stroke Service at the University of California, San Francisco. Dr. Johnston is the Executive Vice Editor of the Annals of Neurology, co-editor of the Journal Watch Neurology and has served on the editorial boards of several other journals. He has been honored with the American Academy of Neurology’s Pessin Prize for Stroke Leadership and the American Stroke Association’s Siekert New Investigator Award. He is also the 2008 recipient of the William Feinberg Award for Excellence in Clinical Stroke through the American Heart Association
Prof David Ingbar: Dr Ingbar is Professor of Medicine, Pediatrics and Integrative Biology and Physiology at the University of Minnesota. He also serves as the Executive Director of the University's Center for Lung Science and Health. Past leadership roles have included service as officer and President of the American Thoracic Society and as President of the APCCMPD (Association of Pulmonary & Critical Care Program Directors). The primary focus of Dr. Ingbar's research is on the repair of the alveolar epithelium after lung injury and the clearance of pulmonary edema fluid. He uses basic molecular biologic and cellular physiologic studies to complement research in animal models of lung development and/or injury and is currently developing a new clinical trial for treatment of pulmonary edema in ARDS. As a clinician, he practices critical care and pulmonary medicine, with an emphasis on caring for critically ill patients with respiratory failure from ARDS and other causes. Finally he is a strong advocate for increasing public awareness of the health impact of respiratory diseases (also including COPD, lung cancer, critical illness and sleep disorders) and support for research to improve outcomes from these conditions.
Prof Bruce G. Robinson:  Dr Robinson is an Endocrinologist, Professor, and Head of the Cancer Genetics Laboratory in the Kolling Institute at Royal North Shore Hospital. He was appointed Acting Dean of the Faculty of Medicine in the University of Sydney in April 2006 and Dean in March 2007.   Professor Robinson graduated from the University of Sydney in 1980 and then undertook studies for a Master of Science degree. His further molecular research work was performed at the Brigham and Women’s Hospital and the Children’s Hospital, Harvard Medical School from 1986-1989 and he was awarded a Doctorate of Medicine from the University of Sydney in 1990. He has developed and led the Cancer Genetics Laboratory since 1990 and has supervised over 30 doctoral and masters students working on the genetic basis for tumour formation and gene therapy. He has published over 200 peer-reviewed scientific articles. In 2003, Professor Robinson was awarded the Daiichi Prize by the Asia and Oceania Thyroid Association for this work on the pathogenesis of thyroid cancer. Prior to his current University appointment, Professor Robinson was Associate Dean (International) in the Faculty of Medicine at the University of Sydney and was Head of the Division of Medicine at the Royal North Shore Hospital from 1998-2006. He also served on the Council of the Endocrine Society of Australia from 2001-2005. He is on the Editorial Board of the International journals ‘Nature, Clinical Practice and Endocrinology’ and ‘Thyroid’. Professor Robinson has a strong interest in furthering relations between Australia and Asia and he is the Founding Chairman of Hoc Mai, the Australia-Vietnam Medical Foundation, which sponsors and supports medical nursing, allied health and scientific exchanges between Australia and Vietnam. He was awarded the People’s Health Medal by the Vietnamese Government in 2008.  He is a Fellow of the Australian Institute of Company Directors.
Prof Pamela B. Davis: Dr Davis is Dean of the School of Medicine and Vice President for Medical Affairs at Case Western Reserve University in Cleveland OH. She received her AB from Smith College, the Ph.D. and M.D. degrees from Duke, and did residency training at Duke in Internal Medicine, then became a clinical associate at the National Institutes of Health, where she trained in pulmonology. In 1981, she moved to Case Western Reserve University, where she rose through the ranks to become the Arline and Curtis Garvin Research Professor of Pediatrics, Physiology& Biophysics, and Molecular Biology, and to direct the Willard A. Bernbaum Center for Cystic Fibrosis Research. In 2003 she became Vice Dean for Research at the School of Medicine, and in 2006, Interim Dean, and in 2007, Dean. Her research interests are the inflammatory response in the lung of patients with cystic fibrosis, as well as gene transfer approaches to the CF basic defect. Her work has been continuously funded for 30 years by the NIH, and she is now the principal investigator of the University’s CTSA. She has received the Paul A. DiSant’Agnese award and the Doris Tulcin Award from the Cystic Fibrosis Foundation, election to the Cleveland Medical Hall of Fame, the Smith College medal, and the Maurice Saltzman Award from the Mt Sinai Health Care Foundation, among other honors, and has steadily been named in “Best Doctors” and “Top Doctors”.
Prof. Carl Borrebaeck: Dr Borrebaeck is chairman of the Department of Immunotechnology, Lund University and program Director of the Strategic Center for Translational Cancer Research – CREATE Health. He received the first chair as professor of Immunotechnology in Scandinavia 1989. His main research interests are cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies. He is a permanent member of the Royal Swedish Academy of Engineering Sciences and deputy vice chancellor of Lund University, with a special responsibility for its innovation system. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy.Prof. Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. He received his Doctor of Science (D.Sc.) in 1979. His research has resulted in several spin-out companies, such as BioInvent International, Alligator Bioscience and Immunovia.

Copyright © 2011 istmed.org All rights Reserved.  International Society for Translational Medicine

Technical support: weicheng